Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Green tea compounds could soothe radiation burns in cancer care

NCT ID NCT07149506

Symptom relief Sponsor: CARLOS FRANCISCO SAAVEDRA GARCIA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether catechins (compounds found in green tea) given as a pill or spray can prevent or treat skin damage caused by radiation therapy. About 162 cancer patients will receive either catechins or a placebo, alongside standard care. The goal is to see if these natural compounds reduce redness, pain, and long-term scarring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
catechins (epicatechin and epigallocatechin gallate)
What this could lead to
If it works, this could offer a simple, accessible way to reduce skin damage from radiation therapy, improving comfort and quality of life for cancer patients.
What could go wrong
This is a single, relatively small Phase 3 trial in Mexico. Catechins may not prove more effective than placebo, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 162 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histopathologically confirmed diagnosis of cancer. * Complete blood count, blood chemistry, and liver function tests within normal ranges. * Availability of an anatomopathological report. * Aged between 18 and 75 years. * Karnofsky performance status (KPS) score \> 60 or an Eastern Cooperative Oncology Group (ECOG) performance status score \< 3. * Candidate for radiotherapy with a prescribed dose of ≥40 Gy or its biological equivalent (EQD2). * Must provide written informed consent to participate in the study. * Must be able to swallow capsules. * Must meet one of the following cohort-specific criteria: 1. Prevention cohort: No clinical evidence of dermatitis at the initiation of radiotherapy. 2. Treatment cohort: Development of grade 1 dermatitis during radiotherapy, with symptom onset within the last 3 days. Exclusion Criteria: * Pregnant or lactating. * Immunocompromised or on chronic therapy with immunosuppressive or immunomodulatory medications. * History of chemical burns or unhealed wounds in the intended radiotherapy treatment area. * Current diagnosis of skin cancer or a known diagnosis of a DNA repair gene defect. * Prior radiotherapy to the area currently being treated. * Known allergy to any of the study compounds. * Currently receiving treatment with bortezomib, sunitinib, ticagrelor, or other antithrombotic agents. Withdrawal Criteria: * Adherence to the study intervention is less than 80%. * Withdrawal of consent. * Suspension of their radiotherapy sessions secondary to an acute infectious disease or the need for hospitalization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibrosis; skin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cutaneous sclerosis Fibrosis localized scleroderma radiodermatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fibrosis; skin Radiation dermatitis Radiation dermatitis acute

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • HRAEB

    León, Guanajuato, 37544, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.